SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: ALL who wrote (4287)5/11/1998 5:41:00 PM
From: Steve Fancy  Respond to of 6136
 
A weighting condition causes this I believe.

regards,

sf



To: ALL who wrote (4287)5/11/1998 6:02:00 PM
From: mod  Read Replies (1) | Respond to of 6136
 
ú New protease inhibitor scrips were down 1.8% over last week's level. Agouron's market share of new protease inhibitor prescriptions was 33.5%, up from 31.8% last week.
ú Total protease inhibitor scrips were up 1.9%, and Agouron's market share was 31.5%, up from 31.0% the week prior.
ú Refill protease inhibitor scrips were up 3.9% versus last week. Viracept's market share of refills was 30.5% for the week of May 1, unchanged from last week.

Dennis


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News